Acelrx Pharmaceuticals, Inc. (ACRX)

$0.6

-0.07

(-10.54%)▲

Live

Insights on Acelrx Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.26M → 253.0K (in $), with an average decrease of 80.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 54.50M → -4.37M (in $), with an average decrease of 136.1% per quarter

  • Vs HLN

    In the last 1 year, Haleon Plc Spon Ads has given 37.4% return, outperforming this stock by 123.4%

Performance

  • $0.56
    $0.67
    $0.60
    downward going graph

    6.67%

    Downside

    Day's Volatility :16.42%

    Upside

    10.45%

    downward going graph
  • $0.55
    $4.86
    $0.60
    downward going graph

    8.33%

    Downside

    52 Weeks Volatility :88.68%

    Upside

    87.65%

    downward going graph

Returns

PeriodAcelrx Pharmaceuticals, Inc.Russel 2000Index (Russel 2000)
3 Months
-39.03%
0.0%
0.0%
6 Months
-11.52%
2.0%
2.0%
1 Year
-83.82%
5.3%
5.3%
3 Years
-97.75%
19.9%
19.9%

Highlights

Market Capitalization
12.3M
Book Value
$0.95
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.0
PEG Ratio
0.0
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
-7770.36%
Return On Assets TTM
-33.27%
Return On Equity TTM
-68.59%
Revenue TTM
253.0K
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
-55.60000000000001%
Gross Profit TTM
-3.3M
EBITDA
-18.0M
Diluted Eps TTM
-3.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.43
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.53
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Acelrx Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1233.33%

Current $0.60
Target $8.00

Company Financials

FY17Y/Y Change
Revenue
8.0M
↓ 53.94%
Net Income
-51.5M
↑ 19.35%
Net Profit Margin
-644.25%
↓ 395.61%
FY18Y/Y Change
Revenue
2.2M
↓ 73.1%
Net Income
-47.1M
↓ 8.46%
Net Profit Margin
-2.2K%
↓ 1547.71%
FY19Y/Y Change
Revenue
2.3M
↑ 6.42%
Net Income
-53.2M
↑ 12.92%
Net Profit Margin
-2.3K%
↓ 133.95%
FY20Y/Y Change
Revenue
5.4M
↑ 136.61%
Net Income
-40.4M
↓ 24.16%
Net Profit Margin
-745.55%
↑ 1580.36%
FY21Y/Y Change
Revenue
2.8M
↓ 47.97%
Net Income
-35.1M
↓ 13.08%
Net Profit Margin
-1.2K%
↓ 499.98%
FY22Y/Y Change
Revenue
1.8M
↓ 37.15%
Net Income
47.8M
↓ 236.06%
Net Profit Margin
2.7K%
↑ 3942.03%
Q1 FY22Q/Q Change
Revenue
442.0K
↑ 22000.0%
Net Income
-8.7M
↑ 9.56%
Net Profit Margin
-2.0K%
↑ 393887.56%
Q2 FY22Q/Q Change
Revenue
570.0K
↑ 28.96%
Net Income
70.7M
↓ 914.65%
Net Profit Margin
12.4K%
↑ 14359.46%
Q3 FY22Q/Q Change
Revenue
507.0K
↓ 11.05%
Net Income
-6.8M
↓ 109.55%
Net Profit Margin
-1.3K%
↓ 13728.38%
Q4 FY22Q/Q Change
Revenue
1.3M
↑ 149.31%
Net Income
54.5M
↓ 907.48%
Net Profit Margin
4.3K%
↑ 5643.46%
Q2 FY23Q/Q Change
Revenue
253.0K
-
Net Income
-4.4M
↓ 181.9%
Net Profit Margin
-1.7K%
-
FY17Y/Y Change
Total Assets
75.6M
↓ 24.44%
Total Liabilities
112.1M
↑ 6.39%
FY18Y/Y Change
Total Assets
120.5M
↑ 59.54%
Total Liabilities
116.3M
↑ 3.76%
FY19Y/Y Change
Total Assets
91.4M
↓ 24.21%
Total Liabilities
132.8M
↑ 14.18%
FY20Y/Y Change
Total Assets
66.3M
↓ 27.43%
Total Liabilities
122.0M
↓ 8.08%
FY21Y/Y Change
Total Assets
77.9M
↑ 17.49%
Total Liabilities
113.8M
↓ 6.77%
FY22Y/Y Change
Total Assets
47.5M
↓ 39.04%
Total Liabilities
25.7M
↓ 77.44%
Q1 FY22Q/Q Change
Total Assets
72.0M
↓ 7.6%
Total Liabilities
110.2M
↓ 3.11%
Q2 FY22Q/Q Change
Total Assets
56.1M
↓ 22.01%
Total Liabilities
23.0M
↓ 79.15%
Q3 FY22Q/Q Change
Total Assets
48.3M
↓ 13.94%
Total Liabilities
20.8M
↓ 9.66%
Q4 FY22Q/Q Change
Total Assets
47.5M
↓ 1.7%
Total Liabilities
25.7M
↑ 23.61%
Q1 FY23Q/Q Change
Total Assets
3.5M
↓ 92.68%
Total Liabilities
3.3M
↓ 87.23%
Q2 FY23Q/Q Change
Total Assets
17.7M
↑ 409.93%
Total Liabilities
7.3M
↑ 122.88%
FY17Y/Y Change
Operating Cash Flow
-29.8M
↑ 1.26%
Investing Cash Flow
-10.0M
↓ 651.13%
Financing Cash Flow
12.3M
↓ 47511.54%
FY18Y/Y Change
Operating Cash Flow
-29.1M
↓ 2.32%
Investing Cash Flow
-10.9M
↑ 9.1%
Financing Cash Flow
75.0M
↑ 508.62%
FY19Y/Y Change
Operating Cash Flow
-51.2M
↑ 76.03%
Investing Cash Flow
-36.6M
↑ 236.15%
Financing Cash Flow
14.5M
↓ 80.74%
FY20Y/Y Change
Operating Cash Flow
-38.5M
↓ 24.77%
Investing Cash Flow
34.1M
↓ 193.37%
Financing Cash Flow
17.0M
↑ 17.33%
FY21Y/Y Change
Operating Cash Flow
-30.0M
↓ 22.08%
Investing Cash Flow
-26.1M
↓ 176.52%
Financing Cash Flow
41.5M
↑ 144.83%
Q1 FY22Q/Q Change
Operating Cash Flow
-8.9M
↑ 11.62%
Investing Cash Flow
20.2M
↓ 554.52%
Financing Cash Flow
-2.1M
↓ 117.6%
Q2 FY22Q/Q Change
Operating Cash Flow
-8.7M
↓ 2.1%
Investing Cash Flow
9.2M
↓ 54.54%
Financing Cash Flow
-2.1M
↑ 0.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-5.2M
↓ 40.11%
Investing Cash Flow
4.4M
↓ 51.57%
Financing Cash Flow
-1.6M
↓ 21.41%

Technicals Summary

Sell

Neutral

Buy

Acelrx Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Acelrx Pharmaceuticals, Inc.
Acelrx Pharmaceuticals, Inc.
-38.47%
-11.52%
-83.82%
-97.75%
-99.19%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.78%
17.2%
13.1%
16.42%
-7.26%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-1.33%
-0.85%
34.27%
9.99%
9.99%
Zoetis Inc.
Zoetis Inc.
-3.36%
6.62%
18.9%
9.85%
95.75%
Viatris Inc.
Viatris Inc.
-12.12%
1.8%
13.01%
-41.0%
-41.0%
Catalent, Inc.
Catalent, Inc.
1.0%
-32.84%
-39.33%
-44.69%
4.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Acelrx Pharmaceuticals, Inc.
Acelrx Pharmaceuticals, Inc.
0.14
NA
0.0
-1.43
-0.69
-0.33
0.0
0.95
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
63.9
63.9
1.87
2.35
0.11
0.08
0.0
18.99
Haleon Plc Spon Ads
Haleon Plc Spon Ads
23.82
23.82
NA
0.0
0.06
0.04
0.01
3.56
Zoetis Inc.
Zoetis Inc.
37.19
37.19
3.53
5.45
0.48
0.14
0.01
10.04
Viatris Inc.
Viatris Inc.
7.07
7.07
NA
2.97
0.09
0.03
0.04
17.38
Catalent, Inc.
Catalent, Inc.
211.02
NA
1.18
1.01
-0.05
0.0
0.0
25.61
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Acelrx Pharmaceuticals, Inc.
Acelrx Pharmaceuticals, Inc.
Buy
$12.3M
-99.19%
0.14
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.0B
-7.26%
63.9
10.54%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.9B
9.99%
23.82
10.78%
Zoetis Inc.
Zoetis Inc.
Buy
$81.3B
95.75%
37.19
26.92%
Viatris Inc.
Viatris Inc.
Hold
$13.0B
-41.0%
7.07
11.88%
Catalent, Inc.
Catalent, Inc.
Buy
$8.4B
4.52%
211.02
-5.43%

Institutional Holdings

  • Rock Springs Capital Management LP

    1.94%

  • TANG CAPITAL MANAGEMENT LLC

    1.19%

  • Vanguard Group Inc

    0.96%

  • Values First Advisors Inc

    0.75%

  • BlackRock Inc

    0.56%

  • Geode Capital Management, LLC

    0.42%

Company Information

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Organization
Acelrx Pharmaceuticals, Inc.
Employees
19
CEO
Mr. Vincent J. Angotti
Industry
Health Technology

Discover More

FAQs